CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
DLBCL 治疗的演变：双特异性抗体
英文原题：The evolving therapy of DLBCL: Bispecific antibodies.
查看英文原题
The evolving therapy of DLBCL: Bispecific antibodies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
双特异性抗体已成功应用于复发/难治性B细胞淋巴瘤（包括DLBCL）的治疗。不同CD3/CD20双特异性抗体的1期研究已显示可控的安全性特征，并在一系列B细胞淋巴瘤中表现出有前景的活性，近期2期研究证实了良好的安全性，并显示即使在重度经治和高危患者中也能获得频繁且持久的完全缓解。本文讨论了这些新药作为单药及联合用药的未来潜在作用，及其在当前和未来治疗格局中的地位，同时也涉及与CAR-T 细胞疗法的关系。
展开英文摘要原文
Bispecific antibodies have been successfully introduced into the management of relapsed or refractory B-cell lymphomas, including DLBCL. Phase 1 studies of the different CD3/CD20 bispecifics have shown manageable safety profile and promising activity in a range of B-cell lymphomas, and recent phase 2 studies confirm the favourable safety and show frequent and durable complete responses even in heavily pre-treated and high-risk patients.
This paper discusses the future potential role of these new agents as single agents and in combinations, and their position in the current and future treatment landscape, also in relation to chimeric antigen receptor T-cell therapy.
论文信息
- 作者
- Hutchings M
- 单位
- Department of Haematology, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark.Denmark
- 文献类型
- 综述
- 期刊
- Hematological oncology2023 Jun
- 原文标识
- PubMed 37294965 · DOI 10.1002/hon.3154